World Journal of Hepatology最新文献

{"title":"Incidence and efficacy of strategies for preventing hepatic encephalopathy following transjugular intrahepatic portosystemic shunt: A meta-analysis.","authors":"Xiao-Tong Xu, Min-Jie Jiang, Yun-Lai Fu, Fang Xie, Jian-Jun Li, Qing-Hua Meng","doi":"10.4254/wjh.v17.i4.104890","DOIUrl":"https://doi.org/10.4254/wjh.v17.i4.104890","url":null,"abstract":"<p><strong>Background: </strong>Hepatic encephalopathy (HE) is a primary complication following transjugular intrahepatic portosystemic shunt (TIPS), but the utility of pharmacological prophylaxis for HE is unclear.</p><p><strong>Aim: </strong>To assess the HE incidence post-TIPS across various groups and the prophylactic efficacies of various medications.</p><p><strong>Methods: </strong>A thorough literature search was performed in PubMed, Web of Science, EMBASE, and the Cochrane Library databases from their inception to November 24, 2024, to collect data regarding HE incidence. The main outcome was HE incidence post-TIPS. A meta-analysis using a random effects model was performed to obtain odds ratios (ORs) and 95% confidence intervals. Statistical analyses were conducted using Stata and RevMan software.</p><p><strong>Results: </strong>This meta-analysis included nine studies with 1140 patients; 647 received pharmacological agents including lactulose, rifaximin, albumin, and l-ornithin-l-aspartate, and 493 did not (controls). (1) In the single-group meta-analysis, the control group had higher short- and long-term HE rates than the drug intervention group. Among patients with and without prior HE, the non-intervention group's HE rates were also higher; (2) Pharmacological prevention post-TIPS significantly reduced HE incidence [OR = 0.59 (0.45, 0.77), <i>P</i> = 0.0001]. Compared with the no prophylaxis, rifaximin reduced the risk of HE after TIPS [OR = 0.52 (0.29, 0.95), <i>P</i> = 0.03], but lactulose did not; (3) In patients without prior HE, pharmacological prevention significantly reduced post-TIPS HE incidence [OR = 0.62 (0.41,0.95), <i>P</i> = 0.03]; and (4) Network meta-analysis showed no significant differences among five prevention strategies.</p><p><strong>Conclusion: </strong>The HE incidence after TIPS was relatively high, and the use of drugs after TIPS may reduce the HE incidence. However, research, especially large-scale randomized controlled trials, is still lacking.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 4","pages":"104890"},"PeriodicalIF":2.5,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of liver imaging and transient elastography among patients with hepatitis C at a safety net hospital.","authors":"Hima Veeramachaneni, Bobak Moazzami, Navila Sharif, Emad Qayed, Lesley S Miller","doi":"10.4254/wjh.v17.i4.105065","DOIUrl":"https://doi.org/10.4254/wjh.v17.i4.105065","url":null,"abstract":"<p><strong>Background: </strong>Liver imaging and transient elastography (TE) are both tools used to assess liver fibrosis and steatosis among people with hepatitis C virus (HCV) infection. However, the diagnostic accuracy of conventional imaging in detecting fibrosis and steatosis in this patient population remains unclear.</p><p><strong>Aim: </strong>To investigate the correlation between steatosis and fibrosis and abnormal findings on liver imaging in patients with HCV.</p><p><strong>Methods: </strong>We conducted a retrospective cross-sectional analysis of patients with HCV at Grady Liver Clinic who had TE exams between 2018-2019. We analyzed the correlation of controlled attenuation parameter and liver stiffness measurement on TE and abnormal findings on liver imaging. Liver imaging findings (hepatic steatosis, increased echogenicity, cirrhosis, and chronic liver disease) were further evaluated for their diagnostic performance in detecting fibrosis (≥ F2, ≥ F3, ≥ F4) and steatosis (≥ S1, ≥ S2, ≥ S3).</p><p><strong>Results: </strong>Of 959 HCV patients who underwent TE, 651 had liver imaging. Higher controlled attenuation parameter scores were observed in patients with abnormal liver findings (<i>P</i> = 0.0050), hepatic steatosis (<i>P</i> < 0.0001), and increased echogenicity (<i>P</i> < 0.0001). Higher liver stiffness measurement values were also noted in those with abnormal liver (<i>P</i> < 0.0001) and increased echogenicity (<i>P</i> = 0.0026). Steatosis severity correlated with hepatic steatosis (<i>r</i> = 0.195, <i>P</i> < 0.001) and increased echogenicity (<i>r</i> = 0.209, <i>P</i> < 0.001). For fibrosis detection, abnormal liver imaging had moderate sensitivity (81.7%) and specificity (70.4%) for cirrhosis (≥ F4), while cirrhosis on imaging had high specificity (99.2%) but low sensitivity (18.3%). Increased echogenicity showed high specificity (92.8%) but low sensitivity (20.9%) for steatosis detection.</p><p><strong>Conclusion: </strong>Liver imaging detects advanced fibrosis and steatosis but lacks early-stage sensitivity. Integrating TE with imaging may improve evaluation in patients with HCV.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 4","pages":"105065"},"PeriodicalIF":2.5,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug development for chronic hepatitis B functional cure: Recent progress.","authors":"Ting Liu, He Wang, Yue Zhao, Ying-Xin Wang, Xue Xing, Peng Gao","doi":"10.4254/wjh.v17.i4.105797","DOIUrl":"https://doi.org/10.4254/wjh.v17.i4.105797","url":null,"abstract":"<p><p>Chronic hepatitis B virus (HBV) infection affects approximately 254 million individuals globally, contributing to significant morbidity and mortality due to HBV-related liver failure and cirrhosis, which result in millions of fatalities each year. Although approved antiviral nucleos(t)ide analogues can effectively suppress HBV replication, their ability to reduce hepatitis B surface antigen (HBsAg) levels in plasma remains limited. The clinical application of the immunomodulator interferon-alpha is restricted by concerns regarding its safety and the severity of associated adverse reactions, rendering long-term administration challenging. Therefore, current drug development efforts for chronic hepatitis B aim to achieve a functional cure, which is defined as HBsAg serological clearance and sustained suppression of HBV DNA. This review discusses recent advancements in novel direct-acting therapeutic strategies for the treatment of chronic hepatitis B by focusing on the progresses in HBV entry inhibitors, monoclonal antibodies, RNA interferences, and other agents that directly target the virus. Furthermore, we discuss the development of immunomodulatory therapies, including TLR-7/8 agonists, immune checkpoint inhibitors, and therapeutic vaccines. In the end, we conclude by highlighting the importance of the rational combination-strategy design to improve the functional cure rate of HBV.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 4","pages":"105797"},"PeriodicalIF":2.5,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is global interest in fasting, intermittent fasting and the liver shifting?","authors":"Athanasios Tselebis, Lina Zabuliene, Ioannis Ilias","doi":"10.4254/wjh.v17.i4.101910","DOIUrl":"https://doi.org/10.4254/wjh.v17.i4.101910","url":null,"abstract":"<p><p>A recent article highlighted the hepatic benefits of intermittent fasting, particularly during Ramadan. However, the rising use of glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (RAs) is altering public behavior, leading to decreased interest in diet and exercise. With a focus on hepatic health, we analyzed global search trends using Google Trends™ data from January 1, 2022 to December 31, 2024, focusing on the keywords \"fasting\", \"intermittent fasting\", \"diet\", \"nutrition\", \"liver\", Semaglutide (\"Ozempic\"™, the most widely known GLP-1 RA) and Tirzepatide (\"Mounjaro\"™, a newer dual GLP-1 and GIP RA). Search interest for \"intermittent fasting\" and \"diet\" showed a significant decline over time (Spearman's rho: -0.582 and -0.605, respectively, both <i>P</i> < 0.001), while interest in \"fasting\" and \"nutrition\" remained stable. Search interest for Semaglutide, Tirzepatide, \"fasting and liver\", \"diet and liver\" and Semaglutide and \"liver\" increased (Spearman's rho: +0.914, +0.936, +0.369, +0.297 and +0.808, respectively, all <i>P</i> < 0.001). These findings suggest a trend of shifting away from traditional dieting toward broader health concerns, likely influenced by the increasing use of GLP-1/GIP RAs.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 4","pages":"101910"},"PeriodicalIF":2.5,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis.","authors":"Thomas Worland, Penelope Hey, Darren Wong, Ross Apostolov, Roseanne Kimberley Chan, Marie Sinclair, Paul Gow","doi":"10.4254/wjh.v17.i4.104056","DOIUrl":"https://doi.org/10.4254/wjh.v17.i4.104056","url":null,"abstract":"<p><strong>Background: </strong>Sarcopaenia is associated with a two-fold higher mortality rate in patients with cirrhosis independent of liver disease severity. Few treatments for cirrhosis related sarcopaenia exist beyond optimal nutritional management.</p><p><strong>Aim: </strong>To assess if rifaximin-α, a minimally absorbed antimicrobial used to manage hepatic encephalopathy (HE), may improve sarcopaenia in cirrhosis through its ammonia lowering and anti-inflammatory properties.</p><p><strong>Methods: </strong>This single-centre retrospective cohort study of patients with prior HE compared patients treated with lactulose alone to those on combination therapy with rifaximin-α. The primary outcome was a change in skeletal muscle area (SMA) as measured by computed tomography over two time points. Secondary outcomes included episodes of spontaneous bacterial peritonitis, variceal bleeding, and gastrointestinal <i>Clostridium difficile</i> infection.</p><p><strong>Results: </strong>Of the 142 patients included, 63 were on rifaximin-α [35% female, median age 57 (51, 62)], and 79 were on lactulose without rifaximin-α [20% female, median age 55 (51, 60)]. Univariate analysis for SMA found that male sex (<i>P</i> < 0.001), hepatocellular carcinoma presence (<i>P</i> = 0.024), and greater baseline body mass index (<i>P</i> = 0.001) were associated with improvement of SMA. Multivariate analysis that adjusted for baseline SMA was performed and found only use of rifaximin-α (<i>P</i> = 0.029) to be associated with improvement of SMA.</p><p><strong>Conclusion: </strong>This study demonstrates a significant independent association between rifaximin-α therapy and muscle mass in patients with cirrhosis and HE. Prospective studies of rifaximin-α therapy examining its impact on sarcopenia are required to assess its potential therapeutic role in this cohort.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 4","pages":"104056"},"PeriodicalIF":2.5,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of <i>Streptococcus salivarius</i> using the digital polymerase chain reaction as a liver fibrosis marker.","authors":"Shuichiro Iwasaki, Akira Také, Haruki Uojima, Kazue Horio, Yoshihiko Sakaguchi, Kazuyoshi Gotoh, Takashi Satoh, Hisashi Hidaka, Yasuhito Tanaka, Shunji Hayashi, Chika Kusano","doi":"10.4254/wjh.v17.i4.102027","DOIUrl":"https://doi.org/10.4254/wjh.v17.i4.102027","url":null,"abstract":"<p><strong>Background: </strong>The <i>Streptococcus salivarius</i> (<i>S. salivarius</i>) group, which produces the enzyme urease has been identified as a potential contributor to ammonia production in the gut. Researchers have reported that patients with minimal HE had an increased abundance of the <i>S. salivarius</i> group, which is a specific change in the gut microbiota that distinguishes them from healthy individuals. The correlation between the aggregation of specific bacterial species and fibrosis progression in chronic liver disease (CLD) is yet to be fully elucidated.</p><p><strong>Aim: </strong>To quantify <i>S. salivarius</i> using digital PCR (dPCR) as a liver fibrosis marker of CLD.</p><p><strong>Methods: </strong>This study retrospectively analysed 52 patients with CLD. To quantify <i>S. salivarius</i> in patients with CLD using dPCR, we evaluated the specificity and sensitivity of <i>S. salivarius</i> bacterial load using dPCR for a type strain. Next, we evaluated the clinical usefulness of dPCR for <i>S. salivarius</i> load quantification for detecting liver fibrosis in patients with CLD. The liver fibrosis stage was categorized into mild and advanced fibrosis based on pathological findings.</p><p><strong>Results: </strong>The dPCR assay revealed that <i>S. salivarius</i> was highly positive for the <i>tnpA</i> gene. The lower limit of quantification for dPCR using the <i>tnpA</i> gene with a 1 μL template comprising 1.28 × 10² CFU/mL was 4.3 copies. After considering the detection range in dPCR, we adjusted the extracted DNA concentration to 5.0 × 10^-4 ng/μL from 200 mg stool samples. The median bacterial loads of <i>S. salivarius</i> in stool sample from patients with mild and advanced fibrosis were 1.9 and 7.4 copies/μL, respectively. The quantification of <i>S. salivarius</i> load was observed more frequently in patients with advanced fibrosis than in those with mild fibrosis (<i>P</i> = 0.032).</p><p><strong>Conclusion: </strong>Quantifying of <i>S. salivarius</i> load using digital PCR is a useful biomarker for liver fibrosis in patients with CLD.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 4","pages":"102027"},"PeriodicalIF":2.5,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the RESET care program: Advancing towards scalable and effective healthcare solutions for metabolic dysfunction-associated liver disease.","authors":"Mariana M Ramírez-Mejía, Froylan D Martínez-Sánchez, Jacqueline Córdova-Gallardo, Nahum Méndez-Sánchez","doi":"10.4254/wjh.v17.i4.105254","DOIUrl":"https://doi.org/10.4254/wjh.v17.i4.105254","url":null,"abstract":"<p><p>In this article, we discuss the recently published article by Soni <i>et al</i>. This study explores the effectiveness of a comprehensive digital health program, RESET care, which integrates personalized dietary plans, structured exercise, and cognitive behavioral therapy delivered through a mobile app equipped with Internet of Things devices such as body composition analyzers and smartwatches. Metabolic dysfunction-associated liver disease (MASLD), a global health burden affecting approximately 25% of the population, demands sustainable lifestyle modifications as its primary management strategy. The study reports that 100% of participants in the comprehensive intervention group (diet + exercise + cognitive behavioral therapy) achieved a weight reduction ≥ 7% (6.99 ± 2.98 kg, 7.00% ± 3.39%; <i>P</i> = 0.002), a clinically significant threshold for MASLD improvement. In addition, participants showed a mean weight reduction of 6.99 kg (101.10 ± 17.85 <i>vs</i> 94.11 ± 17.38, <i>P</i> < 0.001) and a body mass index reduction of 2.18 kg/m² (32.90 ± 3.02 <i>vs</i> 30.72 ± 3.41, <i>P</i> < 0.001). These results underscore the potential of digital health platforms to provide scalable, evidence-based solutions for the treatment of MASLD. While these results highlight the potential of digital platforms in the scalable and personalized management of MASLD, the small study sample size and short duration of follow-up limit the generalizability of the results. Future large-scale, long-term trials are needed to confirm sustained benefits, cost-effectiveness, and broader applicability. This letter contextualizes the study within the evolving landscape of MASLD management and emphasizes the clinical implications of integrating digital technologies into standard care.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 4","pages":"105254"},"PeriodicalIF":2.5,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.","authors":"Valentina Peta, Yuliya Sandler, Olivier Deckmyn, Oksana Duroselle, Elena Vinnitskaya, Sergey Khomeriki, Karina Noskova, Thierry Poynard","doi":"10.4254/wjh.v17.i3.104534","DOIUrl":"10.4254/wjh.v17.i3.104534","url":null,"abstract":"<p><strong>Background: </strong>Noninvasive tests are crucial for the management and follow-up of patients with autoimmune hepatitis, but their validation is limited because of insufficient data.</p><p><strong>Aim: </strong>To investigate the diagnostic performance of three fibrosis noninvasive tests [FibroTest, vibration-controlled transient elastography (VCTE), and the fibrosis-4 index (FIB-4) and two activity biomarkers (alanine aminotransferase (ALT) and ActiTest].</p><p><strong>Methods: </strong>This study enrolled 103 patients for whom liver biopsy, hepatic elastography results, and laboratory markers were available. Diagnostic performance was assessed with receiver operating characteristic (ROC) curves, the Obuchowski measure (OM), and the Bayesian latent class model.</p><p><strong>Results: </strong>FibroTest and VCTE outperformed FIB-4 in cases of significant fibrosis (≥ F2), with areas under the ROC curve of 0.83 [95% confidence interval (CI): 0.73-0.90], 0.86 (95%CI: 0.77-0.92), and 0.71 (95%CI: 0.60-0.80), respectively. The mean (standard error) OM values were 0.92 (0.01), 0.93 (0.01), and 0.88 (0.02) for FibroTest, VCTE, and FIB-4, respectively; FibroTest and VCTE performed comparably, and both were superior to FIB-4 (<i>P</i> = 0.03 and <i>P</i> = 0.005). The areas under the ROC curve values for activity biomarkers were 0.86 (95%CI: 0.76-0.92) for ActiTest and 0.84 (95%CI: 0.73-0.90) for ALT (<i>P</i> = 0.06). The OM values for ActiTest and ALT were 0.92 (0.02) and 0.90 (0.02), respectively (<i>P</i> = 0.005).</p><p><strong>Conclusion: </strong>FibroTest and VCTE outperformed FIB-4 according to the OM. FibroTest-ActiTest facilitated the evaluation of both fibrosis and activity.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"104534"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the next frontier in diagnosing spontaneous bacterial peritonitis.","authors":"Ahmed Tawheed, Mehmet Yalniz, Mubin Ozercan, Ibrahim Halil Bahcecioglu","doi":"10.4254/wjh.v17.i3.102044","DOIUrl":"10.4254/wjh.v17.i3.102044","url":null,"abstract":"<p><p>Spontaneous bacterial peritonitis (SBP) is a common complication of liver failure. It is an acute bacterial infection of the ascitic fluid in patients with liver cirrhosis. SBP presents a significant challenge for hepatologists owing to its associated complications. While diagnostic paracentesis with polymorphonuclear count is highly accurate, it can be troublesome for some patients as it is an invasive procedure with associated risks. Several studies have proposed new diagnostic methods to improve current practices, many of which remain invasive. Although some serum tests show promise in the diagnosis of SBP, the results are still preliminary. Recent advancements in artificial intelligence and machine learning have introduced predictive models and scoring systems for diagnosis. However, these models still lack sufficient sensitivity, specificity, and the ability to effectively assess treatment response.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"102044"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic cirrhosis and decompensation: Key indicators for predicting mortality risk.","authors":"Sara Del Cioppo, Jessica Faccioli, Lorenzo Ridola","doi":"10.4254/wjh.v17.i3.104580","DOIUrl":"10.4254/wjh.v17.i3.104580","url":null,"abstract":"<p><p>Liver cirrhosis represents the final stage of liver diseases. The transition from the compensated to the decompensated form is a critical phase, as it is associated with a negative impact on patient prognosis. Therefore, having a tool to identify patients at higher risk of complications and mortality is an ideal goal. Currently, the validated scores for this purpose are the model for end-stage liver disease score and the Child-Pugh score. However, these scores have limitations, as they do not account for other factors associated with liver cirrhosis that are equally relevant from a prognostic perspective. Among these, alterations in body composition, particularly sarcopenia, increase the risk of mortality and should therefore be considered in the comprehensive assessment of patients with liver cirrhosis.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"104580"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}